Chronic Phase Cohort: To assess the rate of major cytogenetic response (MCyR) of an alternating schedule of axitinib and bosutinib in patients with chronic myeloid leukemia, chronic phase (CML-CP) after failure of/intolerance to >/= 3 tyrosine kinase inhibitors (TKIs) using standard response criteria.